Literature DB >> 27338800

NLRC5 promotes cell proliferation via regulating the AKT/VEGF-A signaling pathway in hepatocellular carcinoma.

Ying-Hua He1, Ming-Fang Li1, Xing-Yan Zhang1, Xiao-Ming Meng1, Cheng Huang1, Jun Li2.   

Abstract

NLRC5, a newly found member of the NLR family and the largest member of nucleotide-binding, has been reported to regulate immune responses and is associated with hepatocellular carcinoma (HCC). We investigated the mechanisms and signaling pathways of NLRC5 in HCC progression. Increased expression of NLRC5, vascular endothelial growth factor-A (VEGF-A) were found in human HCC tissue. There was a positive correlation between NLRC5 and VEGF-A expression and cell proliferation were enhanced in NLRC5-overexpressing HepG2 cells, but inhibited in cells with NLRC5 silencing treatment. Interestingly, we found that up-regulation of NLRC5 also coordinated the activation of PI3K/AKT signaling pathway. An AKT inhibitor LY294002 blocked VEGF-A expression and AKT phosphorylation in HepG2 cells and NLRC5-overexpressing HepG2 cells. These results demonstrate that NLRC5 promotes HCC progression via the AKT/VEGF-A signaling pathway.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  HCC; NLRC5; PI3K/AKT signaling pathway; VEGF-A

Mesh:

Substances:

Year:  2016        PMID: 27338800     DOI: 10.1016/j.tox.2016.06.012

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  15 in total

Review 1.  NLRC5: new cancer buster?

Authors:  Feng Tang; Yadi Xu; Bing Zhao
Journal:  Mol Biol Rep       Date:  2020-01-10       Impact factor: 2.316

2.  MSCs-Derived Extracellular Vesicles Carrying miR-212-5p Alleviate Myocardial Infarction-Induced Cardiac Fibrosis via NLRC5/VEGF/TGF-β1/SMAD Axis.

Authors:  Yijin Wu; Wenying Peng; Miaoxian Fang; Meifen Wu; Min Wu
Journal:  J Cardiovasc Transl Res       Date:  2021-09-10       Impact factor: 3.216

Review 3.  MHC class I transactivator NLRC5 in host immunity, cancer and beyond.

Authors:  Steven X Cho; Saptha Vijayan; Ji-Seung Yoo; Toshiyuki Watanabe; Ryota Ouda; Ning An; Koichi S Kobayashi
Journal:  Immunology       Date:  2020-08-03       Impact factor: 7.397

4.  Ubiquitination Destabilizes Protein Sphingosine Kinase 2 to Regulate Glioma Malignancy.

Authors:  Hongliang Wang; Bing Zhao; Erbao Bian; Gang Zong; Jie He; Yuyang Wang; Chunchun Ma; Jinghai Wan
Journal:  Front Cell Neurosci       Date:  2021-07-07       Impact factor: 5.505

Review 5.  NLRC5 Functions beyond MHC I Regulation-What Do We Know So Far?

Authors:  Szilvia Benkő; Elek Gergő Kovács; Felix Hezel; Thomas A Kufer
Journal:  Front Immunol       Date:  2017-02-17       Impact factor: 7.561

6.  Knockdown of LncRNA SCAMP1 suppressed malignant biological behaviours of glioma cells via modulating miR-499a-5p/LMX1A/NLRC5 pathway.

Authors:  Zheqi Zong; Yichen Song; Yixue Xue; Xuelei Ruan; Xiaobai Liu; Chunqing Yang; Jian Zheng; Shuo Cao; Zhen Li; Yunhui Liu
Journal:  J Cell Mol Med       Date:  2019-06-17       Impact factor: 5.310

7.  NLRC5 promotes cell migration and invasion by activating the PI3K/AKT signaling pathway in endometrial cancer.

Authors:  Yijun Fan; Zhen Dong; Yuchuan Shi; Shiying Sun; Bing Wei; Lei Zhan
Journal:  J Int Med Res       Date:  2020-05       Impact factor: 1.671

8.  Clinical and Molecular Correlates of NLRC5 Expression in Patients With Melanoma.

Authors:  Lei Lv; Qinqin Wei; Zhiwen Wang; Yujia Zhao; Ni Chen; Qiyi Yi
Journal:  Front Bioeng Biotechnol       Date:  2021-07-09

Review 9.  NLRC5: A Potential Target for Central Nervous System Disorders.

Authors:  Lu Zhang; Cui Jiao; Lingjuan Liu; Aiping Wang; Li Tang; Yi Ren; Peng Huang; Jie Xu; Dingan Mao; Liqun Liu
Journal:  Front Immunol       Date:  2021-06-18       Impact factor: 7.561

10.  Suppression of SUN2 by DNA methylation is associated with HSCs activation and hepatic fibrosis.

Authors:  Xin Chen; Wan-Xia Li; Yu Chen; Xiao-Feng Li; Hai-Di Li; Hui-Min Huang; Fang-Tian Bu; Xue-Yin Pan; Yang Yang; Cheng Huang; Xiao-Ming Meng; Jun Li
Journal:  Cell Death Dis       Date:  2018-10-03       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.